Abstract
Historically, squamous cell carcinoma of the anal canal was treated with abdominoperineal resection. Nigro discovered that radiation therapy combined with 5-fluorouracil and mitomycin resulted in high rates of local control and colostomy-free and overall survival without surgical intervention. Recent advances include the integration of PET into staging, radiation treatment planning, disease monitoring, and the use of intensity-modulated radiation therapy. For rectal cancer, clinical trials have established the role for neoadjuvant therapy for T3-4 and/or node-positive tumor presentations. Chemotherapy and targeted agents are under study in both anal and rectal cancers to improve on the standard combinations of chemotherapy and radiation.
Original language | English (US) |
---|---|
Pages (from-to) | 525-543 |
Number of pages | 19 |
Journal | Surgical Oncology Clinics of North America |
Volume | 22 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2013 |
Externally published | Yes |
Keywords
- Anal cancer
- Chemotherapy
- Radiation
- Rectal cancer
- Rectal cancer surgery
- Targeted drug
ASJC Scopus subject areas
- Surgery
- Oncology